Institut Curie
Clinical trials sponsored by Institut Curie, explained in plain language.
-
New hope for aggressive breast cancer: immune combo shows promise
Disease control OngoingThis study tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) plus chemotherapy in 81 women with triple negative breast cancer. It includes two groups: those with early-stage cancer and those with advanced (metastatic) cancer. The goal is to see if the …
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug PEP-010 shows promise in early cancer trial
Disease control OngoingThis early-phase trial tests a new drug called PEP-010 in people with advanced solid tumors that have spread. The study checks if PEP-010 is safe alone or with chemotherapy (paclitaxel or gemcitabine). About 57 adults with metastatic pancreatic, ovarian, or other solid cancers wi…
Phase: EARLY_PHASE1 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for kids with eye cancer: extra chemo may stop spread
Disease control OngoingThis study looks at whether giving chemotherapy (and sometimes radiation) after removing the eye can prevent retinoblastoma from coming back in children. About 195 children with advanced retinoblastoma in one eye took part. The goal is to see if this extra treatment reduces the c…
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New chemo cocktails aim to save eyes in kids with retinoblastoma
Disease control OngoingThis phase 2 trial tests different chemotherapy regimens in 133 children with retinoblastoma, a rare eye cancer. The goal is to shrink tumors and avoid removing the eye or using radiation. Treatments include intravenous and intra-arterial chemotherapy, sometimes combined with las…
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug cocktail targets rare eye cancer
Disease control OngoingThis phase II trial tests whether combining pembrolizumab (an immunotherapy) with lenvatinib (a targeted therapy) can control metastatic uveal melanoma, a rare eye cancer that has spread. About 51 adults are enrolled in two groups: those who have never taken Tebentafusp and those…
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Brain cancer hope: new drug cocktail targets rare lymphoma
Disease control OngoingThis study tests whether adding lenalidomide or ibrutinib to standard chemotherapy (R-MPV) can improve outcomes for adults aged 18-65 with newly diagnosed primary central nervous system lymphoma. The trial has two parts: first, finding the safest dose, then randomly assigning pat…
Phase: PHASE1, PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Blood test may catch pelvic cancer relapse sooner
Diagnosis OngoingThis study looks at whether a blood test that detects tumor DNA can find early signs of cancer returning in people treated for HPV-positive pelvic cancers (like cervical or anal cancer). Researchers will take blood samples from 172 patients during regular follow-up visits. The go…
Phase: NA • Sponsor: Institut Curie • Aim: Diagnosis
Last updated Jun 26, 2026 16:58 UTC
-
New decision tool aims to reduce aggressive End-of-Life cancer care
Knowledge-focused OngoingThis study looks at whether a special decision-making tool can help doctors and patients with advanced non-small cell lung cancer decide when to stop cancer treatments. The goal is to reduce the number of patients receiving chemotherapy or other treatments in their last days of l…
Phase: NA • Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Can yearly MRIs catch second cancers in retinoblastoma survivors?
Knowledge-focused OngoingThis study looks at whether yearly MRI scans can find new head and neck or brain cancers early in people who had hereditary retinoblastoma and were treated with radiation. Researchers will follow 88 participants for 10 years to see if early detection leads to better surgery outco…
Phase: NA • Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:56 UTC